The massive EPS miss and margin compression from tariffs and IPO costs will likely drive significant selling pressure. Watch the earnings call for color on tariff mitigation and whether the raised organic sales guidance can sustain if margins continue deteriorating. The maintained $3.5-$3.6B EBITDA guidance provides a floor but does not offset the earnings disappointment.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 6 $42.01entry
- T+1 · 6mo ago −0.36%α −0.03% · $41.86
- T+5 · 6mo ago −8.24%α −9.37% · $38.55
- T+20 · 6mo ago −17.95%α −20.73% · $34.47
- T+60 · 4mo ago −6.50%α −8.56% · $39.28
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Medline reported Q1 2026 GAAP EPS of $0.01, a 96.6% miss vs consensus of $0.29, and net income fell 25.8% YoY to $239M. Revenue beat at $7.4B (+10.7% YoY) vs $7.16B consensus, and the company raised full-year organic sales guidance to 8.5%-9.5%. However, the massive EPS miss, declining margins (gross margin 25.0% vs 27.5% YoY), and operating cash flow drop of 39.6% overshadow the top-line beat.
Key Financial Metrics
Key Facts
- GAAP diluted EPS of $0.01 vs consensus $0.29, a 96.6% miss
- Net income fell 25.8% YoY to $239M; net income margin compressed to 3.3% from 4.8%
- Revenue of $7.4B beat consensus of $7.16B (+10.7% YoY)
- Gross margin declined 250 bps to 25.0% from 27.5% due to tariff impact and higher COGS
- Adjusted EBITDA fell 10.6% YoY to $776M; Adjusted EBITDA margin 10.6% vs 13.1%
- Operating cash flow dropped 39.6% to $412M; Free Cash Flow down 45.9% to $316M
- Raised full-year 2026 organic sales growth guidance to 8.5%-9.5% (from 8%-9%)
- Maintained Adjusted EBITDA guidance of $3.5-$3.6B
- IPO-related expenses of $27M and employee bonus weighed on earnings
Financial Impact
EPS miss of $0.28 vs consensus; net income decline of $83M YoY; operating cash flow decline of $270M YoY
Risk Factors
- Tariff impact on COGS may persist or worsen, further compressing margins
- IPO-related expenses and employee bonuses may recur in subsequent quarters
- Operating cash flow decline signals weakening cash generation despite revenue growth
- High net leverage of 3.1x limits financial flexibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288704 |
Track record
30 reports on MDLN
4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +8.26% at T+5 after the Oct 21, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bearish 5/10 Entry $36.40 Now $39.17 −7.61% settles Nov 23
- Nov 16, 2026today S-1 Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $42.00 Now $39.17 −6.74% settles Nov 23
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $42.00 Now $39.17 −6.74% settles Nov 23
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $40.71 to $39.17 Now $39.17 −3.78% ▼ −3.78% −2.09% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $40.35 to $42.16 Now $39.17 −2.92% ▲ +4.49% +5.40% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $34.09 to $40.91 Now $39.17 −14.90% ▼ −20.01% −20.59% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $32.12 to $39.64 Now $39.17 +21.95% ▲ +23.41% +26.12% vs SPY
- Oct 21, 202626d ago 8-K Bearish 6/10 Entry $34.88 to $32.00 Now $39.17 −12.30% ▲ +8.26% +8.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers